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As the world approaches the end of the second year of the
COVID-19 pandemic, many countries have come to rely
greatly on the safety afforded by vaccines, available to all
aged 12 years and older, while relaxing other measures in
the general population. In Switzerland, however, less than
60% of the population is fully vaccinated as of 1 Octo-
ber 2021 [1], considerably lagging behind other European
countries. With the highly infectious Delta variant, and
a still significant unvaccinated population, there is broad
consensus that both pharmaceutical and nonpharmaceuti-
cal public health measures will remain relevant to limit fur-
ther spread, especially during the coming winter. Of partic-
ular interest in this context are children below 12 years old,
as no vaccine has been licensed for this age group yet.
A large increase in SARS-CoV-2 infections was observed
in children in many countries recently, including in
Switzerland [2]. Due to the progressive softening of mea-
sures following the mass vaccination campaign, and the in-
creased contagiousness of the Delta variant, it is expected
that the virus will continue to circulate rapidly in this popu-
lation. There has been significant debate on how the educa-
tional system can remain functional, and how to minimise
disruptions of children's well-being and learning, while at
the same time ensuring that virus circulation remains low
so as to protect children and the overall community. Pub-
lic health and school authorities must make decisions as to
which public health measures are appropriate and neces-
sary to reach this goal, in spite of the imperfect evidence
available to date.
The Swiss Society of Paediatrics (SSP) recently stated that
mass testing, mandatory mask wearing, and quarantine or-
ders in schools should be reduced to the “essential min-
imum” to ensure uninterrupted operation of schools [3].
Furthermore, they have argued for a harmonised Switzer-
land-wide strategy, and that vaccination in those >12 years
old will help to mitigate the negative impact of the pan-
demic on children. We strongly support the call for a uni-
form public health strategy for educational institutions
across Switzerland. Furthermore, we fully agree that vacci-
nation uptake in the eligible population must be increased
to protect the age groups not yet eligible for a vaccine.
However, we also believe that the primary goal of any pub-
lic health strategy for schools should be to ensure undis-
turbed, but also safe, education for children. In contrast
to the SSP’s statements, we argue that a number of added
public health measures should be considered “essential” in
order to achieve this goal. In this paper, we respond to the
statements made by the SSP by clarifying the current ev-
idence on the epidemiology and burden of SARS-CoV-2
in children, and the expected benefits of school-based mit-
igation measures. We believe that the following points in
the statement of the SSP require a critical scientific review.
Statements that come directly from the SSP are highlighted
in italics. Our arguments are also briefly summarised in the
appendix.
Disease burden
“The Delta variant does not lead to more severe
COVID-19 courses than previous variants. This statement
is based on clinical experience over 2 months in Switzer-
land, data from the Federal Office of Public Health and
published data from the US.”
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Data regarding the Delta variant and its effects on the
severity of COVID-19 infections continue to emerge, mak-
ing the statement above premature. To the best of our
knowledge, only limited national data assessing the sever-
ity of the disease among children in Switzerland since the
beginning of Delta circulation has been shared; neverthe-
less, several studies suggest that, at least among adults,
Delta may lead to more severe outcomes than previous
variants. A cohort study from Canada found that Delta
“was associated with significant elevations in risk of hos-
pitalisation, intensive care unit (ICU) admission, and death
in younger and older adults", in comparison with non-vari-
ant infections [4]. The same study also found that “Delta
VOC increased hospitalisation risk in children under 10 by
a 2.5 factor (adjusted odds ratio, 95% confidence interval:
1.2 to 5.1) compared to non-VOC" [4] (VOC: variant of
concern). In a UK study looking at all age groups, the re-
sults suggested that “patients with the Delta variant had ap-
proximately two times the risk of hospital admission com-
pared with patients with the Alpha variant” [5].
Consequently, even if the risk of hospitalisation per ex-
posure or infection still remains the same in children, the
overall burden on the health system may be significantly
higher since more people are getting infected with this
more transmissible variant. The statement does, however,
provide a reference to data from the US on children and
adolescent hospitalisations associated with COVID-19
from March 2020 to August 2021 [6]. The cited study
found that, although the proportions of hospitalised chil-
dren and adolescents with severe disease did not show a
statistically significant difference before and during the pe-
riod of Delta predominance, an increase in the circulation
of the highly transmissible Delta variant led to a near-
ly five-fold increase of COVID-19-associated hospitalisa-
tions among children and adolescents, and a nearly 10-fold
increase in the age group 0–4 years, with one in four hospi-
talised children requiring ICU treatment [6]. The estimate
of the proportion of hospitalised children who required in-
vasive mechanical ventilation during the period of Delta
predominance (9.8%) was higher than that earlier in the
pandemic (6.1%), but the comparison of these proportions
was based on a small number of children requiring inva-
sive mechanical ventilation during the Delta period, and
the difference was not statistically significant (p = 0.06).
"The very rare PIMS-TS syndrome (roughly estimated
1:5000 to 1:10,000 infections) has not led to any deaths in
Switzerland so far ..."
Currently, deaths due to the paediatric multisystem inflam-
matory syndrome associated with COVID-19 (PIMS-TS) 
have not yet been reported in Switzerland. Nonetheless, 
COVID-19 has already led to multiple deaths among chil-
dren in other countries. Whereas acute SARS-CoV-2 in-
fections remain generally mild among children, the ab-
solute number of severe cases requiring hospitalisation and 
potentially experiencing long-term consequences increases 
as more children become infected. This was the case for 
the US, where 4461 PIMS-TS cases and 41 deaths meeting 
the PIMS-TS-related case definition were reported, as of 
27 August 2021 [7]. The University Hospital of Geneva 
reported 20 PIMS-TS cases in an estimated 16,000 infec-
tions (around 0.1%) in spring 2021 [8]. Additionally, in Ju-
ly, the Swiss National COVID-19 Science Taskforce esti-
mated that PIMS-TS occurs in around 1:2500 to 1:4000
infections [9]. Other respiratory viruses such as respiratory
syncytial virus (RSV) or influenza are expected to circulate
again this winter. Switzerland, like several other countries,
has already reported an increase in RSV circulation recent-
ly with the relaxation of measures against COVID-19 [10].
Thus, paediatric units, especially paediatric ICUs, are like-
ly to experience an additional burden through otherwise
preventable COVID-19 cases.
Persistent symptoms (long COVID): The incidence and
possible long-term consequences of long COVID are not
addressed at all in the SSP statement. Currently, the inci-
dence of long COVID, especially among children, remains
unclear and varies according to definition and location. For
example, a large study in the UK showed that 4.4% of
children who tested positive for SARS-CoV-2 had symp-
toms for at least 28 days, and 1.8% had symptoms for at
least 56 days [11]. A study from Switzerland showed that
3.7% of seropositive and 2.2% of seronegative school-aged
children (median age 11 years) had symptoms beyond 12
weeks, although the sample size was small [12]. Accord-
ing to recent data from the UK, symptoms were similar in
seropositive children (aged 2 to 11 years) and in a control
group of children without infection (3.2% vs 4.1%) and
overall, the proportion of persons who had symptoms for
at least 12 weeks was lower in children than in adults [13].
However, neurocognitive symptoms such as attention and
learning problems and memory deficits, which are frequent
symptoms of long COVID in adults, were not assessed in
the UK coronavirus infection survey.
Epidemiology
“The seroprevalence (natural contamination), which was
already up to 40% before the start of the 4th wave, depend-
ing on the canton, will continue to increase rapidly.”
As this statement is without reference, it is unclear what
data support this estimate. The Ciao Corona study estimat-
ed that 19% of 2500 Zurich school children had antibod-
ies as of July 2021 [14]. Data from the canton of Geneva,
which was heavily impacted by COVID-19 in 2020, found
a 20.8% seroprevalence in children <6 years old and 31.4%
in 6–11 years old as of July 2021 [15]. Existing data there-
fore highlight that even in strongly affected areas around
70–80% of children remain seronegative, and thus likely
still susceptible to infection and disease.
“The testing strategy in Switzerland since the beginning of
the pandemic has been managed in a way that allows nat-
ural immunization in those under 6 years of age and (par-
tially) in those 6–12 years of age."
The strategy to restrict testing in children under 12 years
was first adopted in July 2020 [16]. Throughout the pan-
demic, the rationale for not testing children for SARS-
CoV-2, even when symptomatic, has been justified by the
SSP’s assumption that only a small proportion of children
would test positive and they rarely transmit SARS-CoV-2
[17]. However, regular testing in schools could play a key
role in the early identification of cases and interruption of
transmission chains, thereby reducing potential disruptions
in the education of children and increasing transparency
and trust in the population [18].
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“Even for the Delta variant, the most important direction
of transmission is from young adults to children, rather
than vice versa, because the age-specific incidence maxi-
mum shifts downward with increasing wave duration. The
most important transmission field remains the family and
household."
Since the opening of schools in Switzerland, several can-
tons have had very large surges of cases in children that
do not correspond to surges in adults. It is highly unlikely
that the majority of these children acquired their infection
outside schools when a large number of children belonging
to the same class or school test positive in a very short
time frame. In the meanwhile, more than half of the adult
population in Switzerland is fully vaccinated. Although
vaccine break-through infections do occur, infections are
far less common among vaccinated than among unvacci-
nated persons [19]. If transmission mostly occurred from
adults to children, we would expect that case numbers in
children would decrease with increasing adult vaccination
rates, rather than increase, as we have observed.
Furthermore, data from the UK found that young people
aged 2–16 years are more likely to be the first case in their
household, even before the predominance of more trans-
missible SARS-CoV-2 variants. The study clearly states
that, “children can transmit within households as well as
in educational settings” [20], and accumulating evidence is
consistent with increased transmission occurring amongst
school children. No such study data are yet available in
Switzerland, and by deliberately choosing not to test chil-
dren or only testing sporadically, important epidemiologi-
cal data on SARS-CoV-2 infection is missed.
Protective measures
The SSP statement is in disagreement with many other
international academies of paediatricians as well as other
large health agencies (e.g., the World Health Organization
[WHO], the US Centers for Disease Control and Preven-
tion [CDC]) concerning preventive measures in education-
al institutions. For example, the American Academy of
Pediatrics strongly advocates for protection measures in
children and schools [21].
Protective measures such as regular testing, mask use, use
of natural ventilation and high-efficiency particulate airfil-
ters (HEPA filters) and vaccination of teachers, are well
known to be very effective without being invasive [22,
23]. It also has been shown in epidemiological studies that
although in-person schooling is associated with increased
household COVID-19 risk, this additional risk is eliminat-
ed with sufficient school-based mitigation measures [24].
The first trial results on vaccination in children aged 5 to
11 years were released by Pfizer recently [25]. The results
show that the vaccine is safe, well tolerated and that it
causes a robust neutralising antibody response. More data
on children aged 2 to 5 years and 6 months to 2 years of
age are expected by the fourth quarter of this year. Many
parents and children are eagerly awaiting the approval of
the vaccine for younger children, and a free circulation of
the virus will increase the risk of infection just before a
protective vaccine will most probably become available.
“Masking mandates should be questioned, especially in
primary schools; mask mandates will not influence the
course of the pandemic in a relevant way”.
Several national and international recommendations on
masks mandates in children exist, although the minimum
age for mask use differs between them. According to the
WHO, masks can be safely used on children above the age
of 5 years [26], while the US CDC recommends masks for
children above the age of 2 years in schools [27]. They al-
so suggest masking people aged ≥2 years in indoor pub-
lic spaces and child care centres as critical measures to
reduce disease burden. Similarly, the Italian paediatric so-
ciety recommends masks in children [28], which are cur-
rently required in Italy above the age of 6. In France, masks
were compulsory for children aged 6 years and older in
schools up to 17 June 2021, and now mask use depends on
the epidemiological situation in the area [29]. Recent da-
ta from the CDC concludes that counties without school
mask requirements experienced larger increases in paedi-
atric COVID-19 case rates compared with counties that
had school mask requirements [30]. Masking of children
and teachers in addition to other mitigation measures was
found to be associated with a significant risk reduction for
COVID-19 in schools in the US [24].
“The effect of air filtration systems in schools has been lit-
tle studied and is not a priority for pandemic control.”
There is little debate on whether improvements in indoor
air quality can lead to reductions in respiratory pathogen
risk, including SARS-CoV-2. Simple ventilation measures
in classrooms promote low CO2 values and thus well-be-
ing, attention and performance [22, 31]. A study in US
schools found that SARS-CoV-2 “incidence was 37% low-
er in schools that required teachers and staff members to
use masks and 39% lower in schools that improved ventila-
tion” [30]. Similarly, a modelling study showed that com-
bined interventions (natural ventilation, masks and HEPA
filtration) were most effective, leading to a ≥30-fold de-
crease in the cumulative dose of viruses absorbed by ex-
posed occupants in a classroom [22].
"Quarantine measures should be used flexibly and with a
sense of proportion. In the case of repetitive testing, they
should be omitted altogether and class quarantines should
only be imposed in the case of several cases (e.g. three per
class within a few days).“
Over the course of the pandemic, quarantine of contacts of
cases has been very effective in containing virus spread.
Quarantines in the form of lock-downs may create enor-
mous societal, economic and health damage. However, fre-
quent testing and quarantines of exposed individuals have
the potential to decrease virus spread within institutions
and limit the size of outbreaks [32]. Thus, testing will ulti-
mately lead to fewer children needing isolation or quaran-
tine. Furthermore, adopting additional measures to prevent
infections in educational settings, as well as vaccination of
all eligible age groups, will further decrease the spread of
SARS-CoV-2. Thus, implementing clear and uniform pub-
lic health measures, which mitigate SARS-CoV-2 circula-
tion in children, will reduce not only morbidity and mor-
tality, but also pandemic-related secondary harm.
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Conclusions
We strongly advocate use of meaningful public health
measures in schools to reduce disruptions in the education
of children and protect those populations that are not yet
eligible for a vaccine. Possible measures have been briefly
summarised by the Swiss National COVID-19 Science
Task Force [33] and also internationally (WHO, CDC) [26,
27] and The Lancet [23]. Adopting the precautionary prin-
ciple will also prevent potential unknown negative long-
term health consequences. By implementing the known ef-
fective measures, both vulnerable children, adults and the
whole healthcare system will be safer. Protecting children
is not only a moral imperative, but will also help us to con-
trol the epidemic situation and ensure continuous educa-
tion during the coming winter.
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Appendix
Table S1
Statements by SSP Counter-arguments
“The Delta variant does not lead to more severe COVID-19 courses than previous vari-
ants. This statement is based on clinical experience over 2 months in Switzerland, da-
ta from the Federal Office of Public Health and published data from the USA.”
No data provided for Switzerland
Data on children still limited and based on small sample sizes
Data on adults shows more severe disease and increased hospitalisation risk
Hospitalisations for children increased with Delta circulation 5–10 fold in US
Opposite conclusions by the authors whose work is cited by SSP
"The very rare PIMS-TS syndrome (roughly estimated 1:5,000 to 1:10,000 infections)
has not led to any deaths in Switzerland so far ..."
COVID19 and PIMS-TS-related deaths have been reported in children in other coun-
tries
Swiss Science Taskforce estimated that PIMS-TS occurs in around 1:2500 to 1:4000
infections
PIMS-TS may strain paediatric units with co-circulation of other viruses
Long COVID and possible long-term consequences not mentioned Incidence of long COVID, especially in children, is still unclear
Varies according to definition and location but it should certainly not be ignored
“The seroprevalence (natural contamination), which was already up to 40% before the
start of the 4th wave, depending on the canton, will continue to increase rapidly.”
No verifiable data source for this seroprevalence
Recent data available for children in Switzerland range between 19% and 31%
70–80% of children are still susceptible to primary infection
“The testing strategy in Switzerland since the beginning of the pandemic has been
managed in a way to allow transmission in those under 6 years of age and (partially) in
those 612 years of age.”
Rationale for this testing strategy was communicated as children being rarely infected
and rarely transmitting the virus in July 2020
Testing increases transparency and trust in the population
“Even for the Delta variant, the most important direction of transmission is from young
adults to children, rather than vice versa, because the age-specific incidence maxi-
mum shifts downward with increasing wave duration. The most important transmission
field remains the family and household."
In Switzerland surge in paediatric cases after school openings does not correspond to
adult incidences
Many concurrent infections in schools make it unlikely that all children infected outside
schools
Accumulating evidence of transmission by children in school and household settings
Increasing vaccination rates in adults do not correlate with decreased infections in chil-
dren
“Masking mandates should be questioned, especially in primary schools; mask man-
dates will not influence the course of the pandemic in a relevant way.”
Masks can be safely used in children according to WHO and the US Centers for Dis-
ease Control and Prevention (CDC)
The US recommends masks for all individuals above the age of 2 in schools
Recent data suggest that mandatory masks slow down the spread of SARS-CoV-2 in
children
“The effect of air filtration systems in schools has been little studied and is not a priority
for pandemic control.”
Implementation of air filters are unlikely to affect the well-being of children and they are
very cheap compared with the costs of a severe disease and school closures.
Many studies exist on effectiveness of air filtration
“Quarantine measures should be used flexibly and with a sense of proportion. In the
case of repetitive testing, they should be omitted altogether and class quarantines
should only be imposed in the case of several cases (e.g. three per class within a few
days)."
Letting the virus spread could potentially contribute to large outbreaks that may de-
mand school-wide closures, thereby involving a larger number of children.
Adopting additional measures will decrease the spread of SARS-CoV-2 and thus also
disruptions by quarantine
Viewpoint Swiss Med Wkly. 2021;151:w30086
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